Targets › CCR4
7 programs from 7 companies in 7 trials: 6 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.
High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1. The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. (UniProt, P51679)
Open in Phaseline: the race on CCR4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yale University | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | T Cell Lymphoma | Nov 2026 |
| Stanford University | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | Sezary Syndrome | Dec 2026 |
| University of Michigan Rogel Cancer Center | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | Cutaneous T Cell Lymphoma | Dec 2026 |
| European Organisation for Research and Treatment of Cancer - EORTC | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | Stage IB-IIB Cutaneous T-Cell Lymphoma | Jan 2027 |
| City of Hope Medical Center | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | Folliculotropic Mycosis Fungoides | Jun 2028 |
| Memorial Sloan Kettering Cancer Center | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 2 | T-Cell Leukemia/Lymphoma, Adult | Nov 2029 |
| John Reneau | Mogamulizumab C-C chemokine receptor type 4 cross-linking agent | CCR4 | Phase 1 | Recurrent Adult T-Cell Leukemia/Lymphoma | Jan 2027 |
Sezary Syndrome (1) Recurrent Adult T-Cell Leukemia/Lymphoma (1) Cutaneous T Cell Lymphoma (1) Folliculotropic Mycosis Fungoides (1) T Cell Lymphoma (1) T-Cell Leukemia/Lymphoma, Adult (1) Stage IB-IIB Cutaneous T-Cell Lymphoma (1)
antibody (5), mixed (2)
Stanford University (1) John Reneau (1) University of Michigan Rogel Cancer Center (1) City of Hope Medical Center (1) Yale University (1) Memorial Sloan Kettering Cancer Center (1) European Organisation for Research and Treatment of Cancer - EORTC (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.